Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer.

Survival outcome of 1592 analyzable patients on four Radiation Therapy Oncology Group (RTOG) studies in inoperable non-small cell lung cancer were studied utilizing a recursive partitioning analysis (RPA). This approach creates a regression tree according to prognostic variables which partitions into homogenous subsets according to survival. Four protocols, RTOG 83-11, 83-21, 84-03 and 84-07 were analyzed. 83-11 and 84-07 were studies utilizing irradiation with alterfractionation; 83-21 and 84-03 were studies evaluating thymocin with irradiation and prophylactic cranial irradiation with thoracic irradiation respectively. Nine pretreatment variables and one treatment variable were analyzed. Adjustment for radiotherapy effect was made in the accelerated treatment protocol (84-07). Overall, median survival for the entire group was 9.0 months with 17% alive at 2 years. Univariate analysis suggests that KPS, < or = 70 vs. 80-100, pleural effusion, weight loss, < or = 5% vs. 5%, age, 60+ vs. < 60, T stage (T1 and T2 vs. T3 and T4) and N stage (N- vs. N+) were important prognastic factors. Radiation dose, sex, race and histology were not univariate prognastic factors. RPA identified KPS as the most significant covariate (median survival 5.9 mos. < or = 70 vs. 9.9 mos. 80-100). Within KPS 80-100 other splits occurred for N stage, age, weight loss and radiation therapy dose. KPS < or = 70 split at pleural effusion only. The best overall RPA tree has four distinct classes with median survival times ranging from 3.3 to 12.6 months. The RPA classes were validated in an independent non-small cell lung cancer dataset. This analysis may allow more intelligent stratification and study-design for future RTOG trials in inoperable non-small cell lung cancer.

[1]  R. Prentice,et al.  A qualitative discrepancy between censored data rank tests. , 1979, Biometrics.

[2]  U Sagman,et al.  Small-cell carcinoma of the lung: derivation of a prognostic staging system. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[4]  C. Mountain The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.

[5]  W. Curran,et al.  Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Sobin,et al.  What do we need beyond TNM? , 1996, Cancer.

[7]  T. Pajak,et al.  A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. , 1993, International journal of radiation oncology, biology, physics.

[8]  G. Hommel A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[9]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R Simon,et al.  Measures of explained variation for survival data. , 1990, Statistics in medicine.

[11]  D. Ettinger,et al.  Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of radiation therapy oncology group 90‐15 , 1995, Cancer.

[12]  J. Cooper,et al.  Phase II Trial of Combination Chemotherapy and Irradiation in Non‐Small‐Cell Lung Cancer, Radiation Therapy Oncology Group 88–04 , 1992, American journal of clinical oncology.

[13]  W. Curran,et al.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. , 1995, Journal of the National Cancer Institute.

[14]  J. Cooper,et al.  Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. , 1991, International journal of radiation oncology, biology, physics.